Clinical Edge Journal Scan

No benefits of supportive self-management program in chronic migraine


 

Key clinical point: A brief group education and supportive self-management program had no beneficial effects on clinically relevant outcomes in patients with chronic migraine or chronic tension type headache and episodic migraine, with or without medication overuse headache.

Major finding: At 12 months, Headache Impact Test scores (adjusted mean difference [AMD] 0.3; P = .56), number of headache days (AMD 0.2; P = .234), duration of headache (estimated difference [ED] 0.4; P = .361), and headache severity (ED 0.2; P = .163) were not significantly different between patients who received self-management intervention vs usual care.

Study details: The data come from CHESS, a randomized controlled trial, including 727 participants with chronic migraine or chronic tension type headache and episodic migraine, with or without medication overuse headache, who received self-management intervention or usual care.

Disclosures: This study was funded by the UK National Institute for Health Research Programme Grants for Applied Research program. Several authors reported receiving grants, personal fees, or honoraria from various sources or owning patent.

Source: Underwood M et al. A supportive self-management program for people with chronic headaches and migraine: A randomized controlled trial and economic evaluation. Neurology. 2022 (Dec 16). Doi: 10.1212/WNL.0000000000201518

Recommended Reading

How COVID-19 pandemic affected headache-related disability in young adults with migraine
Migraine ICYMI
Migraine: A significant risk factor for cardiovascular diseases
Migraine ICYMI
Cluster headache tied to high risk of mental and neurologic disorders
Migraine ICYMI
Commentary: Research on Potential Migraine Triggers, January 2023
Migraine ICYMI
Medication Overuse Headache (MOH): Prevention and Treatment
Migraine ICYMI
Dietary zinc seen reducing migraine risk
Migraine ICYMI
Remote electrical neuromodulation device helps reduce migraine days
Migraine ICYMI
Persistent post-traumatic and new daily persistent headache may indicate abrupt migraine onset
Migraine ICYMI
Chronic migraine: No synergistic effect with erenumab-onabotulinumtoxinA dual therapy
Migraine ICYMI
Chronic migraine: No synergistic effect with erenumab-onabotulinumtoxinA dual therapy
Migraine ICYMI